Current Report Filing (8-k)
September 14 2022 - 3:43PM
Edgar (US Regulatory)
0000948320
false
0000948320
2022-09-08
2022-09-08
0000948320
LFMD:CommonStockParValue0.01PerShareMember
2022-09-08
2022-09-08
0000948320
LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember
2022-09-08
2022-09-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 8, 2022
LIFEMD,
INC.
(Exact
name of Registrant as specified in its charter)
Delaware |
|
001-39785 |
|
76-0238453 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
236
Fifth Avenue, Suite 400
New
York, NY 10001
(Address
of principal executive offices, including zip code)
(866)
351-5907
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.01 per share |
|
LFMD |
|
The
Nasdaq Capital Market |
Series
A Cumulative Perpetual Preferred Stock, $0.0001 per share |
|
LFMDP |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 4.01. |
Changes in Registrant’s Certifying Accountant. |
Effective
September 1, 2022, Friedman LLP (“Friedman”), which served as the independent registered public accounting firm of LifeMD,
Inc. (the “Company”) since 2020, combined with Marcum LLP (“Marcum”). Following the combination, Friedman continued
to operate as an independent registered public accounting firm and wholly-owned subsidiary of Marcum.
On
September 8, 2022, effective immediately, the Audit Committee of the Company approved the dismissal of Friedman and the engagement
of Marcum to serve as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.
Friedman’s
reports regarding the Company’s financial statements for the years ended December 31, 2021 and December 31, 2020 did not contain
any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.
During
the Company’s two most recent fiscal years and the interim period from the end of the most recently completed year through September
8, 2022, the date of Friedman’s resignation, there were no disagreements with Friedman on any matter of accounting principles or
practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of
Friedman, would have caused Friedman to make reference to such disagreement in its report.
The
Company provided Friedman with a copy of the foregoing disclosures and requested that Friedman furnish a letter addressed to the Securities
and Exchange Commission stating whether or not it agrees with the above statements. A copy of Friedman’s letter furnished pursuant
to that request is filed as Exhibit 16.1 to this Current Report on Form 8-K.
Item
9.01. |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
LIFEMD,
INC. |
|
|
|
Dated:
September 14, 2022 |
By: |
/s/
Marc Benathen |
|
|
Marc Benathen |
|
|
Chief
Financial Officer |
Conversion Labs (NASDAQ:CVLB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Conversion Labs (NASDAQ:CVLB)
Historical Stock Chart
From Sep 2023 to Sep 2024